120342-72-5

Upstream product

• 1210-39-5 3,3-diphenyl-2-propenal 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 24892-82-8 1-bromo-2-(1-phenylpropen-1-yl)benzene 
• 140-88-5 ethyl acrylate 
• 2960-66-9 4-oxo-but-2-enoic acid ethyl ester 
• 1002127-15-2 ethyl (E)-5,5-dibromo-2,4-pentadienoate 
• 98-80-6 phenylboronic acid 
• 623-73-4 diazoacetic acid ethyl ester 
• 22825-21-4 3,3-diphenylcyclopropene 

Downstream Products

• 19625-92-4 (E)-5,5-diphenyl-2,4-pentadienoic acid 
• 1002123-50-3 (E)-N-(isoquinolin-5-yl)-5,5-diphenyl-2,4-pentadinenamide 
• 1620657-21-7 diethyl (E)-5,5-diphenyl-2,4-pentadienylphosphate 
• 120342-73-6 (E)-5,5-diphenylpenta-2,4-dien-1-ol 

Relevant academic research and scientific papers

Highly Stereoselective Synthesis of 1,3-Dienes through an Aryl to Vinyl 1,4-Palladium Migration/Heck Sequence

An efficient aryl to vinyl 1,4-palladium migration/Heck sequence was developed for the stereoselective synthesis of 1,3-dienes. High stereoselectivity was observed not only for 1,3-dienes bearing two similar aryl groups at terminal positions, but also for

Silylative cyclopropanation of allyl phosphates with silylboronates

A potassium-bis(trimethylsilyl)amide-mediated cyclopropanation of allyl phosphates with silylboronates has been developed. Unlike the reported copper-catalyzed allylic substitution reactions, the nucleophile selectively attacks at the β-position of the allylic substrates under the present reaction conditions. The mechanism of this process has also been investigated, thus indicating the involvement of a silylpotassium species as the active nucleophilic component.

Discovery of novel 5,5-diarylpentadienamides as orally available transient receptor potential vanilloid 1 (TRPV1) antagonists

We have developed a novel and potent chemical series of 5,5-diphenylpentadienamides for targeting TRPV1 in vitro and in vivo. In this investigation, we examined a variety of replacements for the 5-position of dienamides with the goal of addressing issues related to pharmacokinetics. Our data suggest that substitution with alkoxy groups on the phenyl ring at the 5-position increases their ability to penetrate the blood-brain barrier. This investigation culminated in the discovery of compound (R)-36b, which showed a good pharmacokinetic profile. In vivo, compound (R)-36b was found to be effective at reversing mechanical allodynia in rats in a dose-dependent manner, and it reversed thermal hyperalgesia in a model of neuropathic pain induced by sciatic nerve injury.

Catalytic reactions of carbene precursors on bulk gold metal

Bulk gold metal powder, consisting of particles (5-50 μm) much larger than nanoparticles, catalyzes the coupling of carbenes generated from diazoalkanes (R2C=N2) and 3,3-diphenylcyclopropene (DPCP) to form olefins. It also catalyzes cyclopropanation reactions of these carbene precursors with styrenes. The catalytic activity of the gold powder depends on the nature of the gold particles, as determined by TEM and SEM studies. The reactions can be understood in terms of mechanisms that involve the generation of carbene R2C: intermediates adsorbed on the gold surface.

BENZOFURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Benzofuran derivatives represented by formula (I) or salts thereof: (wherein R1 represents a phenyl group or a hydrogen atom; k is 0 or 1; each of m, n, o, p, and q is an integer of 0 to 5; and each of R2 and R3 represents

3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents

Variously substituted 3,5-dihydroxy-6,8-nonadienoic acids and esters, are blood cholesterol lowering agents and so are useful in the prevention and treatment of cardiovascular diseases such as atherosclerosis.

Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor

A series of N-[4-(3-pyridinyl)butyl]-5,5-disubstituted-pentadienamides was prepared and evaluated for PAF-antagonist activity. Compounds were assayed in vitro in a PAF-binding assay employing washed, whole dog platelets as the receptor source and in vivo after intravenous or oral administration for their ability to prevent PAF-induced bronchoconstriction in guinea pigs. Criteria required for good oral activity in the latter model include an (E,E)-5-phenyl-2,4-pentadienamide, a second phenyl or a four- or five-carbon alkyl moiety in the 5-position of the diene, and an (R)-[1-alkyl-4-(3-pyridinyl)butyl] substituent on the carboxamide nitrogen atom. The alkyl substituent on this side chain can be methyl, ethyl, or cyclopropyl. Two members of this series, [R-(E)]-5,5-bis(4-methoxyphenyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-2,4- pentadienamide (31) and [R-(E,E)]-5-(4-methoxyphenyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-2,4- decadienamide (58), were selected for further pharmacological evaluation. Both were found to be substantially longer acting after oral administration than the corresponding S enantiomers in the guinea pig bronchoconstriction assay. A second in vivo model used to evaluate PAF antagonists determines the ability of test compounds to decrease the area of skin wheals induced by an intradermal injection of PAF. In this model, using both rats and guinea pigs, compounds 31 and 58 were found to be as active as the reference PAF antagonist 3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-2-yl]-1-(4-morpholinyl)-1-propanone (45).